Cancel
Known information
- Has 30 years of experience in R&D
- Spent most of his career working in the fields of Pain and Neuroscience
- Was one of the founders of Convergence Pharmaceuticals
- As Chief Scientific Officer and head of R&D at Convergence Pharmaceuticals, led the company to its successful acquisition by Biogen for $675M in 2015
- Following the acquisition by Biogen, assumed the role of Vice President and Head of the Pain Therapeutic Area
- Prior to Convergence, was Vice President and Head of Pain, Epilepsy, and Migraine drug discovery and early development at GSK
- Held senior roles in Neurology, Psychiatry, and Discovery Sciences during his 20-year career at GSK
- Originally trained as a Biochemist
- Graduated from the University of Dundee
- Had the privilege to work with Sir Philip Cohen, who was, at the time, the world’s third most cited professor
About Eliem Therapeutics
Eliem Therapeutics is a biopharmaceutical company focused on developing therapies for neuronal excitability disorders, with key projects including ETX-155 for major depressive disorder and focal onset seizures.
Report inaccurate information
